California Pacific Medical Center Research Institute
Trial Pipeline
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
NCT05988385
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
NCT05077280
Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
NCT01750619
Trial of Parkinson's And Zoledronic Acid
NCT03924414
The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).
NCT02845401
Adherence Monitoring For Substance Abuse Clinical Trials
NCT01867476
The PERFusion Use in Stroke Evaluation Study
NCT01387113
Proactive Ethics Intervention to Improve Intensive Care Unit (ICU) Care
NCT00996814
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
NCT00713284
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 2 |
What the Pipeline for California Pacific Medical Center Research Institute Shows
According to the ClinicalTrials.gov registry, California Pacific Medical Center Research Institute is linked to 9 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 33% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 44% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for California Pacific Medical Center Research Institute reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for California Pacific Medical Center Research Institute is Intensive Care Unit Days with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.